Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | CASP1 | P29466 | 3/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8037759 | 0.92 | CASP3 (0.53) | MDM4TP53CASP3CASP1TNF | |
| SCHEMBL30826385 | 0.92 | CASP3 (0.53) | MDM4TP53CASP3CASP1TNF | |
| SCHEMBL30641530 | 0.92 | CASP3 (0.53) | MDM4TP53CASP3CASP1TNF | |
| SCHEMBL119369 | 0.92 | CASP3 (0.53) | MDM4TP53CASP3CASP1TNF | |
| SCHEMBL30802532 | 0.92 | CASP3 (0.53) | MDM4TP53CASP3CASP1TNF | |
| SCHEMBL29398340 | 0.92 | CASP3 (0.53) | MDM4TP53CASP3CASP1TNF | |
| SCHEMBL10187049 | 0.92 | CASP3 (0.53) | MDM4TP53CASP3CASP1TNF | |
| SCHEMBL29400275 | 0.92 | CASP3 (0.53) | MDM4TP53CASP3CASP1TNF | |
| SCHEMBL29398655 | 0.90 | TLR2 (0.48) | MDM4TP53CASP3CASP1TNF | |
| SCHEMBL31166669 | 0.90 | CASP1 (0.50) | MDM4TP53CASP3CASP1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564632-B2 | Conjugates of biomolecule and use thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2026-03-03 | — | — | US | disclosed |
| WO-2024200838-A1 | NEW ODILORHABDINS ANALOGUES AS ANTIBIOTICS AGAINST MULTI-RESISTANT BACTERIA | NOSOPHARM (FR) | 2024-10-03 | — | — | WO | disclosed |
| US-20240271329-A1 | CYCLIC COMPOUND LIBRARY AND CONSTRUCTION METHOD THEREFOR | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-111670051-B | Biomolecular conjugates and uses thereof | 亚飞（上海）生物医药科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4309665-A1 | CYCLIC COMPOUND LIBRARY AND CONSTRUCTION METHOD THEREFOR | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2022193902-A1 | CYCLIC COMPOUND LIBRARY AND CONSTRUCTION METHOD THEREFOR | 亚飞上海生物医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | CD47, FCGR2A, CD40 | MDM4 3454/4885TP53 156/4885CASP3 237/4885 |
| US-12564632-B2 | Conjugates of biomolecule and use thereof | FCGR2A, FCGR3B, TNFRSF9 | MDM4 2149/4885TP53 35/4885CASP3 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.